Study Overview: This study is for adults with a type of blood cancer called B-cell Lymphoma. The specific types are relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) and Classic Follicular Lymphoma (cFL). "Relapsed" means the cancer came back after treatment, and "refractory" means it didn't respond to treatment. The study tests a new drug called epcoritamab to see if it's safe. Epcoritamab is given by injection under the skin (subcutaneous) and participants will get increasing doses until the full dose is reached.
Key Details:
- Duration: Participants will receive treatment in 28-day cycles.
- Location: The study takes place at about 80 sites in the USA.
- Participation: Regular visits to a clinic or hospital are required, with frequent checks through medical tests.
Adults who have tried at least 1 prior treatment for DLBCL or 2 for cFL may join. They must have a life expectancy of more than 3 months and meet specific health conditions. Those with certain infections or central nervous system involvement cannot join. The study aims to enroll about 184 adults.